Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Table 2 One-year occurrence of major adverse cardiovascular events.

	Fluvastatin N = 78	Placebo N = 78	OR	95%CI	P
Death	1 (1.3)	4 (5.1)	0.24	0.02-2.20	0.37
Nonfatal MI	2 (2.6)	4 (5.1)	0.49	0.08-2.74	0.68
UAP	6 (7.7)	16 (20.5)	0.32	0.11-0.87	0.037
Urgent revascularization	6 (7.7)	14 (17.9)	0.38	0.14-1.05	0.09
PCI	5 (6.4)	13 (16.7)	0.34	0.12-1.01	0.08
CABG	1 (1.3)	2 (2.6)	0.49	0.04-5.56	1.0
Stroke	1 (1.3)	3 (3.8)	0.32	0.03-3.19	0.62
New hospitalization	14 (17.9)	34 (43.6)	0.28	0.13-0.59	<0.001
Death+MI	3 (3.8)	8 (10.3)	0.35	0.09-1.37	0.21
Death+MI+UAP++Urgent revascularization	9 (11.5)	19 (24.4)	0.40	0.17-0.95	0.038
Death+MI+UAP+Stroke++Urgent revascularization	10 (12.8)	21 (26.9)	0.40	0.17-0.92	0.044

Values are expressed as No. (%). MI, myocardial infarction; UAP, unstable angina pectoris; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery

ISSN: 1745-6215